Srinivas Ayyadevara | Cardiovascular and neurodegenerative disorders | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Srinivas Ayyadevara | Cardiovascular and neurodegenerative disorders | Best Researcher Award

Prof. Dr. Srinivas Ayyadevara, University of Arkansas for Medical Sciences and CAVHS (GRECC), United States

Dr. Srinivas Ayyadevara is a distinguished Research Health Scientist and Professor whose impactful work in aging, neurodegeneration, and cardiovascular research has spanned over two decades. Currently serving at the Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences (UAMS), Dr. Ayyadevara is known for his pioneering studies on protein aggregation, mitochondrial dysfunction, and cellular stress responses. His multidisciplinary background in biochemistry, genetics, and molecular biology has enabled him to address critical questions in age-related diseases, particularly Alzheimer’s disease. His career is marked by an exceptional publication record, strong federal research contributions, and a long-standing commitment to mentoring and collaboration. With a proven track record in translational science, Dr. Ayyadevara exemplifies the qualities sought in a top-tier biomedical researcher and continues to make significant contributions to the health and longevity of aging populations.

Publication Profile: 

Google Scholar

Strengths for the Award:

  1. Extensive Research Portfolio:
    Dr. Ayyadevara has a prolific track record of peer-reviewed publications across high-impact journals in fields of aging, neurodegeneration, cardiovascular biology, and molecular mechanisms of disease.

  2. Innovative Contributions:
    His studies have pioneered understanding of protein aggregation, mitochondrial dysfunction, autophagic failure, and pharmacological interventions for Alzheimer’s and age-related pathologies. His recent contributions using neural-network analysis and systems biology approaches are particularly cutting-edge.

  3. Multidisciplinary Expertise:
    With formal education in genetics, chemistry, biochemistry, and molecular biology, and research spanning model organisms to human data, Dr. Ayyadevara’s versatility is a hallmark of modern biomedical research excellence.

  4. Translational Impact:
    His work addresses major public health concerns (e.g., Alzheimer’s, heart disease, aging), with findings that could directly impact therapeutic strategies, particularly for aging populations and veterans.

  5. Longevity of Research Commitment:
    Over two decades of continuous research experience, including long-term federal service with the VA system, reflects sustained productivity and dedication.

  6. Collaborative Leadership:
    He co-authors with multidisciplinary teams, mentors junior scientists, and contributes to community-building within aging and biomedical research.

Areas for Improvement:

  1. Principal Investigator Leadership Visibility:
    While Dr. Ayyadevara contributes significantly to many studies, increased leadership as the sole or lead PI on large federal grants or multi-center collaborations would further highlight his independent research stature.

  2. Recognition and Awards:
    Despite an exceptional track record, public awards, keynote lectures, or national recognition (e.g., from NIH, VA, or gerontological societies) appear underreported. Greater visibility in these areas could bolster his profile.

  3. Patent/Technology Translation:
    The available information does not indicate patent filings or commercialization of findings. Highlighting translational milestones may strengthen his profile for broader impact assessments.

Education:

Dr. Srinivas Ayyadevara’s educational journey began in India, where he earned a B.Sc. (Hons) in Botany, Chemistry, and Biochemistry (1985) and an M.Sc. in Genetics (1987) from Osmania University. He later pursued an M.Sc. in Chemistry at Louisiana Tech University in the U.S. (1993), before completing his Ph.D. in Biochemistry and Molecular Biology at the University of Arkansas for Medical Sciences (1999). His diverse educational background reflects a robust foundation in life sciences, integrating classical genetics with modern molecular biology. This solid academic preparation has greatly informed his experimental approaches in biogerontology and neurodegeneration. His transition from plant and microbial studies to mammalian and human-focused research reflects a clear trajectory toward translational science aimed at combating aging and disease. This interdisciplinary and international academic training positions him well for leadership in cutting-edge biomedical research.

Experience:

Dr. Ayyadevara has over 25 years of biomedical research experience, including more than 17 years as a Research Health Scientist at the Central Arkansas Veterans Healthcare System. Since 2008, he has held this GS-13 level position, contributing to VA research in aging and neurodegeneration. As of July 2025, he serves as a Professor in the Department of Geriatrics at UAMS, following his role as an Associate Professor. His career includes hands-on lab leadership, collaboration with clinical investigators, and senior authorship of high-impact publications. He has led or co-led numerous translational studies involving Alzheimer’s disease, cardiovascular aging, proteomics, and mitochondrial function. Dr. Ayyadevara’s work frequently bridges basic science with clinical relevance, making tangible contributions to veteran health and public aging research. He is a trusted mentor and team leader whose experience spans model organisms, human tissue studies, and molecular interventions aimed at extending healthspan.

Research Focus:

Dr. Srinivas Ayyadevara’s research centers on understanding the molecular underpinnings of aging and age-associated diseases, with a particular emphasis on Alzheimer’s disease, cardiovascular aging, mitochondrial dysfunction, and protein aggregation. He employs model organisms like C. elegans, as well as human and mouse models, to study mechanisms of cellular stress, proteostasis, and genetic resilience to aging. A recurring theme in his work is the role of protein crosslinking and mitochondrial signaling in neurodegenerative and cardiac pathologies. His group is recognized for developing novel tools like the Leave-One-Out-Analysis (LOOA) to study protein interactions in aggregates and identifying actionable targets for drug development. Recently, he has investigated how common pharmaceuticals like ezetimibe and TDZD analogs reduce pathological aggregation. His research merges systems biology, proteomics, and pharmacological screening—offering promising therapeutic avenues for age-related diseases.

Publications Top Notes:

  1.  Mitochondria in aging and age-associated diseases – Mitochondrion, 2025

  2.  Altered protein homeostasis in cardiovascular diseases contributes to Alzheimer’s-like neuropathology – Basic Res Cardiol, 2025

  3.  Ezetimibe reduces Alzheimer’s risk by targeting 14-3-3G::Hexokinase interaction – Aging Biol, 2024

  4.  Model systems reveal pathways to reduce cryoprotectant toxicity – Cryobiology, 2024

  5.  LOOA: A web tool for protein interaction prediction in aggregation studies – Bioinformation, 2024

  6.  Neural-network analysis identifies drug targets in Alzheimer’s amyloid interactome – iScience, 2023

  7.  Small molecules rescue ApoE4-induced autophagy failure in Alzheimer’s disease – Commun Biol, 2024

  8.  Heart attack increases ER stress and aggregation in heart and brain – Mol Cell Biochem, 2023

  9.  TDZD analogs improve neurodegeneration models and extend lifespan in C. elegans – Pharmaceuticals, 2023

  10.  Proteomic analysis of ischemic heart and exosome modulation – Biochem Biophys Rep, 2023

Conclusion:

Dr. Srinivas Ayyadevara is highly suitable for the Best Researcher Award. His consistent, high-impact research over the years, especially in aging, neurodegeneration, and systems biology, combined with his commitment to veteran health and translational outcomes, makes him an outstanding candidate. With a few enhancements in national visibility and leadership designation, his already strong profile could rise to the top tier of internationally recognized researchers.

Shima Shafiee | Cell Structure Analysis | Best Researcher Award

Published on by Cell Biologist

Dr. Shima Shafiee | Cell Structure Analysis | Best Researcher Award

Dr. Shima Shafiee, Razi University, Iran

Shima Shafiee is an accomplished Iranian researcher specializing in computer systems architecture and bioinformatics, with a strong focus on machine learning applications in biological data analysis. She recently earned her Ph.D. in Computer Engineering from Razi University, where she focused on predictive modeling of protein-peptide binding interactions. Currently under consideration at the IDEL Lab, Shahid Bahonar University of Kerman, Shima has authored numerous national and international publications. With a rich background in algorithm optimization and artificial intelligence, her research stands at the intersection of computational biology, deep learning, and evolutionary algorithms. Shafiee’s work has contributed to the development of predictive tools in bioinformatics, such as DP-site and SPPPred, and she consistently ranks at the top of her academic cohort. Her ability to integrate traditional computer engineering concepts with advanced biological research makes her a notable candidate for the Best Researcher Award.

Publication Profile: 

Google Scholar

Strengths for the Award:

  1. Strong Academic Foundation
    Dr. Shafiee has a stellar academic record, graduating first in her Ph.D. class at Razi University with a CGPA of 3.77 and a thesis grade of 3.98, under the supervision of respected experts in computer engineering and bioinformatics.

  2. Innovative Interdisciplinary Research
    Her research bridges computer systems architecture, machine learning, and bioinformatics, with notable contributions to protein-peptide binding prediction, a critical domain in drug discovery and computational biology.

  3. High-Impact Publications
    She has published in IEEE/ACM Transactions, Applied Soft Computing, and Methods, reflecting both quality and visibility in international forums. Tools like SPPPred and DP-site demonstrate her practical impact in bioinformatics.

  4. Research Originality and Versatility
    Dr. Shafiee has developed hybrid models combining genetic programming, support vector machines, and deep learning, with practical tools and open-source contributions.

  5. Early Recognition and Outreach
    She has been active in academic dissemination since 2015, with selected papers in national and international conferences, showing early promise and consistency.

  6. Teaching and Mentorship
    Through her roles as a lecturer at multiple institutions, she has contributed to academic growth at the grassroots level.

Areas for Improvement:

  1. International Collaboration & Visibility
    While her publication quality is strong, Dr. Shafiee could expand her global visibility through collaborations with international research labs, EU Horizon, or NIH-funded projects.

  2. Post-Ph.D. Grant Applications
    She could benefit from applying for independent research grants or postdoctoral fellowships to lead projects that could shape the future of AI in biology.

  3. Open-Source Software and Data Availability
    While her models are impactful, increased accessibility via open-source repositories (e.g., GitHub) would boost reproducibility and encourage broader adoption.

  4. Industry Impact Metrics
    More emphasis on industry collaborations, patents, or application of models in clinical/biotech settings would enhance translational impact.

Education:

Shima Shafiee completed her Ph.D. in Computer Engineering (2016–2024) from Razi University, specializing in Computer Systems Architecture. Her dissertation titled “Application of learning-based models in predicting of protein-peptide binding interactions” earned her a thesis grade of 3.98/4.00 and an overall CGPA of 3.77. She worked under the guidance of Dr. Abdolhossein Fathi and Dr. Ghazaleh Taherzadeh, focusing on bioinformatics using deep learning, ensemble learning, and evolutionary algorithms. Prior to her Ph.D., she was ranked third in her Master’s program (2015). Shafiee’s educational background is rooted in computational problem-solving, algorithm development, and cross-disciplinary research involving biological data. Her consistent academic excellence and high-ranking performance culminated in her being recognized as the top Ph.D. student in 2025, a testament to her dedication and scholarly capabilities. Her education blends rigorous theory with innovative applied research, making her exceptionally well-prepared for high-impact contributions in academia and industry.

Experience:

Shima Shafiee’s experience spans both academic and applied computer engineering roles. She began her journey with an internship at Kimia Pardaz Pars Company (2013). Between 2015 and 2016, she served as a lecturer for computer fundamentals at Fajr High School and Al-Zahra Seminary School in Jiroft, where she taught introductory computer science to pre-university students. These experiences highlight her foundational teaching skills and outreach to educational institutions in her community. Her major academic contribution began during her Ph.D., where she collaborated with IDEL Lab and contributed to developing tools like SPPPred and DP-site, combining genetic programming, support vector machines, and deep learning to predict protein-peptide binding regions. Her experience uniquely blends educational outreach, algorithmic development, and publication-driven research in machine learning, optimization, and computational biology, reflecting her versatility and impact across the scientific and academic spectrum.

Awards & Honors:

Shima Shafiee has earned multiple distinctions recognizing her academic and research excellence. In 2015, she was named the third-place student in her Master’s program, demonstrating early academic excellence. Her continuous dedication to research and scholarship led her to be recognized as the first-place student in her Ph.D. program in 2025. One of her papers was selected at the 2nd International Congress of Electrical Engineering, Computer Science, and Information Technology (2015), highlighting the innovation and relevance of her early research in optimization algorithms. Her high publication output, including appearances in top-tier venues like IEEE/ACM Transactions on Computational Biology and Bioinformatics and Applied Soft Computing, reflects a consistent standard of excellence. These honors collectively showcase her as a standout figure in her field, with both academic and applied contributions acknowledged at national and international levels.

Research Focus:

Shima Shafiee’s research lies at the intersection of machine learning, bioinformatics, and computational systems engineering. Her primary focus is the prediction of protein-peptide binding interactions using intelligent algorithms such as genetic programming, ensemble models, and deep learning techniques. She has proposed several innovative hybrid models combining sequence-based and structure-based features to identify critical interaction residues. Her doctoral thesis and publications have led to the development of tools like SPPPred and DP-site, which aid in biological sequence analysis, with applications in drug discovery, protein function prediction, and biomedical engineering. Shafiee also has a strong background in optimization algorithms, especially particle swarm optimization (PSO), applied to computationally intensive problems like bin packing. Her ability to blend theoretical computing with practical biological data analysis makes her contributions valuable to both computational scientists and biologists, and positions her as a leading candidate for research recognition awards in AI and bioinformatics.

Publications Top Notes: 

  • 🧠 SPPPred: sequence-based protein-peptide binding residue prediction using genetic programming and ensemble learning (IEEE/ACM TCBBS, 2022)

  • 🔍 Prediction of protein–peptide-binding amino acid residues regions using machine learning algorithms (CSICC, 2021)

  • 🧬 Combination of genetic programming and SVM-based prediction of protein-peptide binding sites (Journal of Computing and Security, 2021)

  • 🧪 Prediction of protein–peptide binding residues using classification algorithms (IEEE Bioengineering Conf, 2020)

  • 🧠 A Review of the Uses of AI in Protein Research (Peptide Science Conf, 2019)

  • 🤖 DP-site: dual deep learning method for protein-peptide interaction site prediction (Methods, 2024)

  • 🧬 Protein-peptide interaction region prediction using generative sampling & ensemble DL (Applied Soft Computing, 2025)

  • 🧠 Comparing classification vs. segmentation predictors in protein-peptide interaction (CSICC, 2025)

  • 🧬 Leveraging structure-based and learning-based predictors in protein-peptide interaction (ICCKE, 2024)

  • 📘 Application of learning-based models in protein-peptide binding (Ph.D. Dissertation, 2024)

Conclusion:

Dr. Shima Shafiee is a highly suitable candidate for the Best Researcher Award based on her academic excellence, interdisciplinary research achievements, and consistent contributions to the fields of artificial intelligence and bioinformatics. Her ability to bridge computer science and biological challenges has resulted in meaningful and applicable solutions. She has displayed originality, depth, and foresight in her work, developing novel methods that align with modern computational biology trends.

Xinmei Zhang | Endometriosis | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Xinmei Zhang | Endometriosis | Best Researcher Award

Prof. Dr. Xinmei Zhang, Women’s Hospital, School of Medicine, Zhejiang University, China

Prof. Xinmei Zhang is the Chief Physician at the Women’s Hospital, School of Medicine, Zhejiang University, and a professor in the same institution. With over two decades of clinical and academic experience in gynecology, she has become a leading expert in the diagnosis and treatment of gynecological diseases, particularly endometriosis and adenomyosis. Her work integrates clinical excellence with cutting-edge research, focusing on women’s reproductive health, minimally invasive surgery, and gynecologic oncology. Prof. Zhang also holds several editorial roles in international journals and actively collaborates with institutions worldwide including MD Anderson Cancer Center (USA), Cochin Hospital (France), and Fudan University (Brazil). As an ambassador and key committee leader in multiple gynecological associations, she contributes significantly to shaping global standards in reproductive health. Her numerous publications and international recognition underscore her commitment to advancing women’s health through translational research and global collaboration.

Publication Profile: 

Orcid

Scopus

Strengths for the Award:

  1. Consistent Academic Excellence

    • Over 20 years of service in clinical and academic gynecology.

    • Held dual leadership roles: Chief Physician and Professor at Zhejiang University.

    • Ph.D. in medicine and visiting scholarship in Australia show strong academic foundation and international exposure.

  2. Extensive Research Contributions

    • A strong record of peer-reviewed publications (2025–2019), many in indexed international journals.

    • Research impact areas: endometriosis, adenomyosis, gynecologic oncology, drug delivery, and minimally invasive surgery.

  3. Editorial and Leadership Roles

    • Editorial board member of top journals including Annals of Translational Medicine and Chinese Journal of Obstetrics and Gynecology.

    • Vice/Chairman positions in national and international medical societies, including the World Endometriosis Association.

  4. International Collaborations

    • Collaborates with leading institutions in USA (MD Anderson), France (Cochin Hospital), Brazil, and Russia, enhancing research diversity and relevance.

  5. Innovative Methods

    • Introduced novel cell culture models, biomarker-driven diagnostic tools, and nanoparticle-based drug delivery systems.

Areas for Improvement:

  1. Interdisciplinary Expansion

    • While strong in clinical research, greater integration with AI, bioinformatics, or digital diagnostics could elevate research scope.

  2. Public Health Impact

    • Scaling research from clinical environments to community-based studies or low-resource settings would increase societal impact.

  3. Global Recognition

    • While collaborations exist, active presence in global conferences, panels, or international guideline development would boost global profile.

Education:

Prof. Xinmei Zhang received her Ph.D. in Medicine from Zhejiang University between August 2009 and December 2011. She pursued advanced clinical training and research with a focus on gynecology and reproductive health. Earlier in her career, she served as a visiting scholar at Queensland University Adult Hospital, Australia, in 2003, where she gained international exposure in clinical research and practice. This experience enriched her global perspective and deepened her understanding of women’s health issues. Her rigorous academic background laid the foundation for a strong career in translational gynecology, merging laboratory discoveries with clinical application. Prof. Zhang’s education has equipped her with both theoretical knowledge and practical skills in molecular medicine, surgical gynecology, and women’s reproductive disorders. As an educator and researcher, she continues to mentor young clinicians and researchers in China and abroad, ensuring the next generation inherits both technical expertise and a strong ethical foundation.

Experience:

Prof. Xinmei Zhang has been serving as a Chief Physician at the Women’s Hospital, Zhejiang University since 2005, and was promoted to Professor at the School of Medicine in 2021. Her work encompasses clinical leadership, research coordination, and educational mentorship. As the head of the Department of Gynecology and co-lead at the Zhejiang Provincial Key Laboratory for Precision Diagnosis and Therapy of Major Gynecological Diseases, she spearheads initiatives in translational medicine. Her editorial appointments include prominent journals such as the Chinese Journal of Obstetrics and Gynecology and Annals of Translational Medicine. She is also a recognized leader in several professional organizations, including serving as Vice Chairman in multiple national and regional medical associations. Prof. Zhang has conducted multi-center clinical studies, developed advanced surgical techniques, and collaborated internationally on research projects. Her rich experience makes her a cornerstone in China’s gynecological research and healthcare innovation.

Research Focus:

Prof. Xinmei Zhang’s research centers on endometriosis, adenomyosis, and gynecologic oncology, with a strong emphasis on the molecular mechanisms, immune pathways, and targeted therapies. She investigates inflammatory chemokines (e.g., CCL2, CCR4, CCL18), epithelial-mesenchymal transition, neuroangiogenesis, and tumorigenic signaling pathways, bridging lab-based molecular research with clinical treatment strategies. Her studies explore novel biomarkers for diagnosis (e.g., ROMA Index for endometrial cancer) and innovative therapeutic models like curcumin–paclitaxel nano-delivery systems. Prof. Zhang has also pioneered methods for isolating ectopic stromal and epithelial cells to model adenomyosis, thus facilitating personalized medicine approaches. Her cross-border collaborations strengthen her work’s global relevance, especially in addressing complex conditions that impact women’s reproductive health and quality of life. With a publication record in high-impact journals, she contributes both to fundamental science and its translation into patient care. Her research is backed by strong institutional support and an extensive global academic network.

Publication Top Notes: 

CCL2/CCR4 participates in mast cell-mediated epithelial mesenchymal transition in endometriosis – Reproductive BioMedicine Online (2025)
CCL18 promotes endometriosis by increasing endometrial cell migration and neuroangiogenesis – European Journal of Histochemistry (2024)
A method for isolating and culturing ectopic epithelial and stromal cells to study human adenomyosis – Archives of Gynecology and Obstetrics (2023)
A method for isolating and culturing ectopic epithelial and stromal cells to study human adenomyosis – Preprint Version (2023)
ROMA Index Is an Effective Predictor for Advanced Endometrial Cancer before Surgery – Disease Markers (2022)
Anemia-Associated Platelets and Plasma Prothrombin Time Increase in Patients with Adenomyosis – Journal of Clinical Medicine (2022)
Long-Term Pregnancy Outcomes of Patients with Diffuse Adenomyosis after Double-Flap Adenomyomectomy – Journal of Clinical Medicine (2022)
RON Mediates Tumor‐Promoting Effects in Endometrial Adenocarcinoma – BioMed Research International (2021)
Co-Delivery of Curcumin and Paclitaxel by “Core-Shell” Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer – International Journal of Nanomedicine (2019)
Comparisons of the efficacy and recurrence of adenomyomectomy for severe uterine diffuse adenomyosis via laparotomy versus laparoscopy – Journal of Pain Research (2019)

Conclusion:

Prof. Xinmei Zhang is a highly qualified candidate for the Best Researcher Award. Her sustained contributions to women’s health, innovative clinical and molecular research, strong global collaborations, and leadership in academic medicine represent the ideal profile of a world-class researcher. Her work not only advances science but translates directly into improved patient care—an essential criterion for this award.

Sukanta Nath | Cancer Research | Distinguished Scientist Award

Published on by Cell Biologist

Dr. Sukanta Nath | Cancer Research | Distinguished Scientist Award

Dr. Sukanta Nath, Atal Bihari Vajpayee Regional Cancer Centre, India

Dr. Sukanta Nath is a dedicated Research Scientist with over 13 years of experience in molecular biology, virology, and cancer research. He currently serves at the Atal Bihari Vajpayee Regional Cancer Centre, Agartala, Tripura, where he has led several impactful studies in oral cancer patient care. Holding a Ph.D. in Biotechnology from Gauhati University, Dr. Nath has consistently demonstrated excellence in scientific inquiry, especially in clinical intervention studies. His collaborative works with clinical and academic experts have produced over 10 peer-reviewed publications in reputed journals. Dr. Nath’s research emphasizes evidence-based nursing practices, molecular diagnostics, and the improvement of post-surgical outcomes in cancer patients. Known for his commitment to translational research, Dr. Nath is playing a pivotal role in bridging molecular science with patient-centered care in North-East India. His multidimensional expertise and scholarly contributions make him a deserving candidate for recognition as a Distinguished Scientist.

Publication Profile: 

Scopus

Strengths for the Award:

  1. Extensive Research Experience:
    With over 13 years of hands-on experience in molecular biology, cancer research, and virology, Dr. Nath has a well-established research career that aligns with the award’s standards.

  2. Focused Contributions to Cancer Research:
    His work at Atal Bihari Vajpayee Regional Cancer Centre has significantly contributed to oral cancer patient management, particularly through randomized intervention studies improving postoperative recovery and mental health.

  3. High Research Output:
    He has authored or co-authored 10+ peer-reviewed publications, many of which focus on novel and under-explored aspects such as nursing intervention in cancer care—a progressive and human-centered approach.

  4. Multidisciplinary Approach:
    Dr. Nath bridges molecular diagnostics, clinical research, and public health, evident in his work on HPV molecular epidemiology and AML treatment reviews.

  5. Collaborative and Institutional Impact:
    His collaborations with clinicians, nurses, and academic institutions highlight his team-oriented and translational research vision, helping integrate academic outputs into real-world healthcare.

Areas for Improvement:

  1. International Exposure:
    Dr. Nath could enhance his academic profile with international fellowships, collaborative projects, or presentations at global conferences, which would add broader recognition and perspective to his impactful regional work.

  2. Grant Acquisition & Leadership Roles:
    Documented principal investigator roles or research funding/grant awards would strengthen his leadership credentials in scientific research.

  3. Recognition & Awards:
    While he has a commendable publication record, more national or state-level recognitions, fellowships, or memberships in professional bodies (like ICMR, DBT, etc.) would boost his candidacy for national-level honors.

Education:

Dr. Sukanta Nath’s academic foundation is rooted in the biological sciences, beginning with a B.Sc. in Botany, Zoology, and Physiology from Calcutta University (2003, First Class). He went on to complete his M.Sc. in Biotechnology from Utkal University in 2006, securing First Class (67%). His research potential culminated in a Ph.D. in Biotechnology from Gauhati University, awarded in 2018, where he specialized in molecular biology and translational biomedical science. His education reflects a progressive mastery of theoretical and applied biotechnology, allowing him to engage in complex interdisciplinary research. Despite modest early academic challenges in higher secondary and matriculation, Dr. Nath’s academic trajectory sharply ascended, reflecting perseverance and intellectual growth. His doctoral training equipped him with specialized skills in molecular diagnostics, research design, and bioanalytical tools, which now form the backbone of his professional research work in cancer and infectious disease.

Professional Experience:

Dr. Nath is presently serving as a Research Scientist at the Atal Bihari Vajpayee Regional Cancer Centre, Tripura, since April 2020, where he conducts pivotal research on postoperative outcomes and interventions in oral cancer patients. Previously, he worked as a Research Associate at the College of Fisheries, Central Agricultural University, Tripura (2018–2019), contributing to institutional-level biotech projects. In 2017–2018, he served as a Molecular Scientist and Quality Manager at Agility Diagnostics Pvt. Ltd., Delhi, a NABL-accredited molecular diagnostics lab, where he gained valuable experience in molecular testing and lab quality control. With over 13 years of interdisciplinary experience, Dr. Nath has successfully combined clinical and molecular biology expertise, making impactful contributions to oncology, diagnostics, and public health. His adaptability across academic, clinical, and industry environments illustrates his wide-ranging capabilities as a biomedical researcher and project leader.

Awards and Honors:

While specific named awards are not listed in the provided resume, Dr. Sukanta Nath’s contributions have earned peer recognition through frequent lead and co-author roles in high-impact publications. His ongoing collaboration with clinicians, epidemiologists, and nursing researchers has positioned him as a sought-after expert in cancer-related intervention studies in North-East India. He has been an instrumental figure in pioneering randomized clinical studies assessing fatigue, anxiety, and quality of life in post-surgical oral cancer patients—work that has been accepted in internationally indexed journals. His contributions to the molecular epidemiology of HPV in Indian women also reflect national relevance. The volume and scope of his work, alongside a sustained publication record, underline a distinguished career in translational cancer research. Nomination for the Distinguished Scientist Award is a well-aligned recognition of his achievements and continued potential to contribute at the national level.

Research Focus:

Dr. Nath’s primary research interest lies in molecular biology, oncology, and virology, with a strong emphasis on translational studies that impact patient care. He has led intervention-based research evaluating the role of nursing and clinical protocols in improving postoperative recovery among oral cancer patients. His work assesses anxiety, fatigue, and quality of life post-surgery using evidence-based methodologies. Dr. Nath has also contributed significantly to molecular epidemiology, particularly studying the distribution of high-risk HPV genotypes among women in North-East India. His experience in diagnostics and biotech allows him to approach clinical problems from both biomedical and molecular perspectives, making his research integrative and impactful. The focus on nursing intervention studies, rarely explored in Indian cancer centers, demonstrates his commitment to holistic cancer care. His future goals involve scaling such studies to wider patient populations and contributing to national cancer care protocols.

Publications Top Notes:

  1. 📘 Effectiveness of a supportive educational intervention on pain and physical function among patients undergone abdominal surgery: A randomized controlled trial

  2. 📗 Effectiveness of comprehensive nursing intervention on alleviating postoperative fatigue and anxiety in patients with oral cancer

  3. 📕 Molecular epidemiology and genotype distribution of genital high-risk human papillomavirus among women in North–East India

  4. 📙 Effectiveness of Nursing Interventions on Anxiety among Postoperative Oral Cancer Patients in Regional Cancer Centre, Tripura

  5. 📒 Importance of Nursing Intervention in Alleviating Post-Surgical Fatigue for Patients with Oral Cancer

  6. 📓 Does comprehensive nursing intervention improve post-surgical anxiety in patients with oral cancer?

  7. 📔 Post-Surgical Evaluation of Quality of Life in Patients with Oral Cancer: An Intervention Study from India

  8. 📚 Assessment of Fatigue and Quality of Life amongst Post-Operative Oral Cancer Patients: A Randomized Case Control Study

  9. 📙 Effect of Comprehensive Nursing Intervention on Anxiety and Quality of Life in Postoperative Patients with Oral Cancer

  10. 📗 Prognosis and Treatment in Acute Myeloid Leukemia: A Comprehensive Review

Conclusion:

Dr. Sukanta Nath has demonstrated dedicated service, innovative research, and strong scientific output in the fields of molecular biology and oncology, particularly with a patient-centric approach to oral cancer care. His work addresses a critical healthcare challenge in North-East India and proposes practical solutions backed by rigorous research methodologies.

 

Lei Shi | Tumorigenesis | Distinguished Scientist Award

Published on by Cell Biologist

Mr. Lei Shi | Tumorigenesis | Distinguished Scientist Award

Mr. Lei Shi, Lanzhou University, China

Dr. Lei Shi is a distinguished cancer biologist and molecular pathologist, currently serving as a Professor and Group Leader at the School of Public Health, Lanzhou University, China. With an international career spanning Germany, the UK, and China, Dr. Shi has significantly contributed to our understanding of long non-coding RNAs (lncRNAs), KRAS-mediated tumorigenesis, and lung cancer biology. He earned his Ph.D. from Ludwig Maximilian University of Munich, and completed postdoctoral training at the CRUK Manchester Institute, one of the world’s premier cancer research centers. His interdisciplinary research bridges cancer signaling, immunotherapy, and molecular genetics. Dr. Shi has been the recipient of multiple national and international grants and has authored numerous high-impact publications in journals such as Nature Communications, Molecular Cancer, and Cell Death & Differentiation. His research plays a pivotal role in advancing personalized cancer therapy and diagnostics, making him a strong contender for the Distinguished Scientist Award.

Publication Profile: 

Orcid

Scopus

Strengths for the Award:

  1. Extensive Expertise in Tumorigenesis
    Dr. Shi has built a deep and consistent research track record in lung cancer biology, KRAS signaling, and non-coding RNAs—critical areas in modern tumorigenesis research. His work spans oncogene-driven pathways, epigenetics, and RNA biology, which are all highly relevant to the theme of this award.

  2. Strong International Training and Collaborations
    His academic path includes a Ph.D. in Germany (LMU Munich), a postdoctoral fellowship in the UK (University of Manchester/Cancer Research UK), and leadership in China—demonstrating international impact and collaboration.

  3. Proven Research Leadership
    As a Group Leader and Professor at Lanzhou University, Dr. Shi has led grants from both national and provincial Chinese funding bodies, showcasing strong institutional leadership and research independence.

  4. High-Impact Publications
    Dr. Shi has multiple first-author and corresponding-author publications in top-tier journals like Nature Communications, Molecular Cancer, Cell Death & Differentiation, Cancer Research, and others. This indicates a sustained contribution to scientific knowledge with measurable impact.

  5. Focus on Translational Relevance
    His work on KRAS-mediated tumorigenesis, lncRNAs in cancer, microRNA regulation, and drug resistance directly contributes to potential cancer therapies and diagnostics, aligning with the translational emphasis of many distinguished awards.

  6. Mentorship and Emerging Talent Development
    Multiple publications list junior co-authors under his supervision, showing that he actively mentors young scientists and builds collaborative research teams.

Areas for Improvement:

  1. Broader Recognition in Global Awards
    While Dr. Shi has an impressive research footprint, there is limited mention of international awards, editorial roles, or keynote presentations, which are often considered markers of distinguished global leadership.

  2. Clinical Translation or Patents
    The profile would benefit from stronger clinical application indicators, such as patents, clinical trials, or biotechnology translation, to further demonstrate real-world impact.

  3. Broader Research Diversification
    Although his expertise is deep in KRAS and RNA biology, engaging with emerging areas like AI in cancer research, organoid modeling, or immune-oncology interfaces could amplify his multidisciplinary influence.

Education:

Dr. Lei Shi’s academic journey is deeply rooted in life sciences and molecular pathology. He obtained his Bachelor’s degree in Veterinary Medicine (2003–2007) from Heibei North University, China, followed by a Master’s degree (2007–2010) in Agricultural Microbiology at Huazhong Agricultural University, where he developed his early interest in pathogenic mechanisms. He then pursued his Ph.D. (Dr.rer.nat) in Molecular Pathology (2011–2014) at the Ludwig Maximilian University of Munich, Germany, under the mentorship of Prof. Dr. Heiko Hermeking. His doctoral research explored the transcriptional regulation of tumor suppressors and oncogenes. This academic progression built a solid foundation in molecular oncology, leading to a postdoctoral fellowship (2015–2021) at the Cancer Research UK Manchester Institute and Lung Cancer Centre of Excellence, UK. Dr. Shi’s diverse education has provided him with a global and translational perspective on cancer biology, strengthening his leadership in molecular oncology research today.

Professional Experience:

Dr. Lei Shi is a Professor and Group Leader (2021–present) at Lanzhou University, where he heads translational cancer biology research within the School of Public Health. Prior to this, he held a prestigious Postdoctoral Research Fellow role (2015–2021) at the Cancer Research UK Manchester Institute, affiliated with The University of Manchester. There, he conducted cutting-edge research on KRAS-driven lung cancers, drug resistance mechanisms, and RNA therapeutics. Earlier, he was a Ph.D. researcher (2011–2014) at Ludwig Maximilian University of Munich, delving into the regulatory roles of p53 and lncRNAs. His professional experience reflects a continuum of cancer research from fundamental science to translational applications. Dr. Shi’s team at Lanzhou University is now exploring new therapeutic targets for non-small cell lung cancer and virus-associated cancers. He has secured multiple prestigious national and international grants and is actively mentoring the next generation of cancer researchers in China.

Research Focus:

Dr. Lei Shi’s research centers on the molecular mechanisms of cancer development and progression, with a primary focus on long non-coding RNAs (lncRNAs), KRAS oncogene signaling, and RNA-based therapeutic strategies. His lab investigates how lncRNAs modulate gene expression, interact with microRNAs, and influence tumor microenvironment and immune response, particularly in non-small cell lung cancer (NSCLC) and virus-related malignancies. Dr. Shi is also exploring transcriptional feedback loops, including interactions between HIF1A-AS2 and MYC, to unravel how oncogenic pathways fuel metastasis. His postdoctoral work revealed KRAS-induced microRNA regulation, significantly advancing the understanding of RNA biology in cancer. Dr. Shi’s research integrates bioinformatics, functional genomics, and clinical samples to identify novel biomarkers and therapeutic targets. His contributions are paving the way for precision oncology, making a significant impact on early diagnosis, patient stratification, and drug resistance profiling in solid tumors, especially lung cancer.

Publications Top Notes: 

  1. The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy – Molecular Cancer (2025)

  2. Long non-coding RNA-encoded micropeptides: functions, mechanisms and implications – Cell Death & Discovery (2024)

  3. p53-regulated lncRNAs in cancers: from proliferation and metastasis to therapy – Cancer Gene Therapy (2023)

  4. Long non-coding RNA HIF1A-As2 and MYC form a double positive feedback loop in NSCLC – Cell Death & Differentiation (2023)

  5. Long non-coding RNAs in virus-related cancers – Reviews in Medical Virology (2022)

  6. Prognostic and immunotherapeutic roles of KRAS in Pan-Cancer – Cells (2022)

  7. A KRAS-responsive long non-coding RNA controls microRNA processing – Nature Communications (2021)

  8. Diverse roles of long non-coding RNA in viral diseases – Reviews in Medical Virology (2020)

  9. Vulnerability of drug-resistant EML4-ALK lung cancer to transcriptional inhibition – EMBO Mol Med (2020)

  10. KRAS induces lung tumorigenesis through microRNAs modulation – Cell Death & Disease (2018)

  11. The immunological and prognostic landscape of TFAP4 in cancer (scRNA-seq study) – Archives of Biochemistry and Biophysics (2025)

Conclusion:

Dr. Lei Shi is highly suitable for the Distinguished Scientist Award in Tumorigenesis Research. His exceptional publication record, international training, leadership in cancer biology, and dedication to translational science make him a standout candidate. With ongoing contributions and future expansion into cross-disciplinary domains, his research trajectory is aligned with the highest standards of scientific distinction.

Jean-Marc LEMAITRE | Cellular Senescence Aging | Best Researcher Award

Published on by Cell Biologist

Dr. Jean-Marc LEMAITRE | Cellular Senescence Aging | Best Researcher Award

Dr. Jean-Marc LEMAITRE, INSERM UMR1183, France

Jean-Marc Lemaitre is a French biomedical researcher internationally renowned for his groundbreaking work on cellular reprogramming and aging reversal. Born on October 14, 1963, he is currently based at the Institute for Regenerative Medicine and Biotherapies (IRMB) in Montpellier, where he serves as co-director. His work has transformed the understanding of how aged cells can be rejuvenated, offering new hope for regenerative therapies. With a strong academic and clinical research background, Lemaitre has authored over 100 scientific articles and books on senescence, stem cells, and epigenetics. He is a board member of several scientific societies and journals, and continues to drive research at the frontier of aging science. Lemaitre is also a public science communicator and author, helping bridge cutting-edge biology with societal challenges related to aging. His passion for improving human health through innovative science places him at the forefront of biomedical research in France and globally.

Publication Profile:

Orcid

Google Scholar

Strengths for the Award:

  1. Pioneering Work in Aging Reversal
    Lemaitre was among the first scientists to show that senescent human cells can be rejuvenated, contributing significantly to cellular reprogramming and epigenetic longevity science.

  2. High-Impact Publications & Scientific Output
    Authored or co-authored over 100 scientific works, including in Nature Aging, Molecular Cell, Scientific Reports, and PNAS. His studies are cited globally in aging, regenerative medicine, and stem cell therapy.

  3. Institutional Leadership
    As Co-Director and Co-founder of IRMB, he manages a research institute with 180+ staff, positioning him as a key scientific leader in France.

  4. Scientific Recognition
    Member of scientific editorial boards and committees (e.g., Cells journal, Ligue Contre le Cancer), and board member of FSSCR, reflecting sustained leadership in the stem cell field.

  5. Translational & Interdisciplinary Impact
    His research has led to clinical insights in dermatology, osteoarthritis, and cardiology, demonstrating broad biomedical relevance beyond aging biology.

  6. Public Engagement and Science Communication
    Author of books like “Guérir la Vieillesse” and “Décider de son âge”, he bridges scientific knowledge with public interest in health and longevity.

Areas for Improvement:

  1. Expanded International Collaborations
    While Lemaitre collaborates across disciplines, further integration into global consortia or partnerships with biotech/pharma could amplify the translational value of his work.

  2. Visibility in Policy or Global Aging Initiatives
    Participation in policy advisory boards or international aging panels (e.g., WHO, UN Decade of Healthy Aging) would enhance his influence in shaping public health approaches to aging.

  3. Startups or Technology Transfer
    Commercialization of his discoveries (e.g., senescence therapies or reprogramming protocols) through startups or IP licensing would elevate his impact on innovation and real-world application.

Education:

Jean-Marc Lemaitre’s academic journey is rooted in molecular and developmental biology. He earned his DEA (Diplôme d’Études Approfondies) in Developmental Biology from Paris 6 University in 1991. His Doctorate (PhD) followed in 1995 from Paris 7 University, with research conducted at the esteemed Institut Jacques Monod in molecular and cellular biology. His early focus on the fundamental processes of cell development laid the groundwork for his future expertise in aging and regenerative medicine. In 2005, Lemaitre earned his Habilitation to Direct Research (HDR) from Montpellier University Medical School, a prestigious credential that allowed him to lead independent research projects. His educational path reflects a consistent and deep engagement with life sciences and a strong commitment to academic excellence. These milestones set the foundation for his leading role in cellular reprogramming and senescence-related research at both national and international levels.

Experience:

Jean-Marc Lemaitre has amassed over 30 years of professional experience in biomedical research, with a major focus on aging, senescence, and regenerative medicine. Since 2015, he has served as Co-Director and Cofounder of the IRMB (Institute for Regenerative Medicine and Biotherapies), which now houses over 180 researchers. His professional base is at the Saint Eloi Hospital in Montpellier, where he contributes both to translational research and clinical collaborations. Between 2014 and 2018, he held a Contrat d’Interface at CHU Montpellier, strengthening ties between research and healthcare. His pioneering work in cellular reprogramming earned international acclaim for demonstrating that senescent human cells could be rejuvenated using induced pluripotent stem cell (iPSC) technology. Lemaitre also plays leadership roles in research consortia such as the FHU REGENHAB and is an elected member of scientific committees, including the LIGUE Contre le Cancer du Septentrion. His experience is both deep and influential in shaping modern aging research.

Awards and Honors:

Jean-Marc Lemaitre has been recognized multiple times for his leadership and innovation in biomedical science. He was elected to the Scientific Committee of the LIGUE Contre le Cancer du Septentrion in 2019, reflecting his growing influence in translational medicine. In 2015, he co-founded and became Co-Director of IRMB, an institute now pivotal in stem cell and regenerative therapies. From 2014 to 2018, he was awarded a Contrat d’Interface at CHU Montpellier, enhancing integration between research and clinical practice. His work has also earned him positions on international editorial boards, including the “Cells” journal since 2020. In 2007, he co-founded and became a board member of the French Society for Stem Cell Research (FSSCR). These honors reflect not only the quality of his scientific contributions but also his dedication to mentorship, institution-building, and public engagement in science. He remains a key figure in aging and regenerative medicine globally.

Research Focus:

Jean-Marc Lemaitre’s research centers on cellular aging, senescence, and regenerative medicine. He is internationally renowned for demonstrating that aged or senescent human cells can be reprogrammed back to a pluripotent state—effectively reversing aging markers. His team has been at the forefront of identifying epigenetic mechanisms involved in aging and developing short reprogramming protocols to extend healthspan. He works extensively on senotherapeutics—interventions targeting the senescent cells that drive aging and disease—and has published seminal studies on skin aging, musculoskeletal regeneration, and systemic rejuvenation. Lemaitre is also a thought leader in developing blood-based epigenetic clocks to monitor aging and predict mortality. His integrative approach blends molecular biology, stem cell science, and translational medicine to uncover ways to slow or reverse aging processes. His work opens promising therapeutic avenues for treating age-related diseases, improving healthspan, and potentially redefining biological age through cellular reprogramming technologies.

Publications Top Notes:

  1. Disc-Derived iPSCs and Environmental Cues for Nucleus Pulposus Regeneration (Tissue Eng Part A, 2025)

  2. Blood-Based Epigenetic Clock for Intrinsic Capacity and Mortality (Nat Aging, 2025)

  3. Niacinamide and Hyaluronic Acid for Skin Aging: Clinical Correlation (Sci Rep, 2024)

  4. Décider de son âge (Book, 2024 – Allary Editions)

  5. Therapeutic Approaches Targeting Senescent Cells (Cells, 2023)

  6. Guérir la Vieillesse (Book, 2022 – Humensciences)

  7. Single Short Reprogramming Increases Healthspan (Aging, 2022)

  8. Epigenetic Mechanism Linking Early Reprogramming to Lifespan (Aging Cell, 2022)

  9. DNMT1-Driven 4D Genome Rewiring in Senescence (Molecular Cell, 2020)

  10. DNA Replication Timing as Marker in Progeroid Diseases (PNAS, 2017)

Conclusion:

Jean-Marc Lemaitre is a highly deserving candidate for the Best Researcher Award. He combines groundbreaking research in cellular aging and epigenetics with institutional leadership and public engagement. His work has transformed the understanding of biological aging, making him one of the most influential biomedical scientists in Europe in this domain. The award would not only recognize his scientific excellence but also highlight the increasing importance of healthy aging, regenerative medicine, and cellular rejuvenation in modern medicine.

Lobna Hajji-Hedfi | interaction plant host-microorganisms | Best Researcher Award

Published on by Cell Biologist

Dr. Lobna Hajji-Hedfi | interaction plant host-microorganisms | Best Researcher Award

Dr. Lobna Hajji-Hedfi, Regional Centre of Agricultural Research of Sidi Bouzid, Tunisia

Dr. Lobna Hajji Ep Hedfi is a Tunisian Assistant Professor in Phytopathology at the Regional Centre of Agricultural Research of Sidi Bouzid. With a robust scientific footprint, she specializes in plant-microbe interactions, biological disease control, and fungal biodiversity. Born in Kairouan, Tunisia, in 1982, she resides in Chott-Meriem, Sousse. She actively contributes to the SPADD-LR03AGR02 research laboratory and is a board member of Microbial Biosystems and Frontiers in Scientific Reports journals. Dr. Hajji is internationally recognized, recently earning the Ethel Mary Doidge Medal (2024) by the International Mycological Association and receiving a prestigious scholarship from NUFFIC (Netherlands). With numerous high-impact publications and international collaborations, she advances sustainable agriculture and microbial solutions for plant health. Her interdisciplinary research and dedication make her a strong candidate for the Best Researcher Award.

Publication Profile: 

Orcid

Scopus

✅ Strengths for the Award:

  • Prolific Research Output: Over 18 high-impact publications from 2024–2025 in peer-reviewed journals and international book chapters.

  • Scientific Leadership: Editorial board member for Microbial Biosystems and Frontiers in Scientific Reports, indicating peer recognition.

  • International Recognition: Awarded the prestigious Ethel Mary Doidge Medal by the International Mycological Association (2024), a major honor for early-career African researchers.

  • Innovation in Sustainable Agriculture: Her work focuses on biological control, fungal endophytes, and eco-friendly pathogen suppression, aligning with SDG goals.

  • Global Collaboration: Co-authored with scientists from Europe, North Africa, Asia, and Sub-Saharan Africa, emphasizing strong research networking.

  • Capacity Building: Beneficiary of MSP NUFFIC scholarships (Netherlands) in 2023 and 2024, enhancing her international expertise.

📉 Areas for Improvement:

  • Increased Funding Leadership: More visibility as a principal investigator (PI) in large-scale or competitive international research grants would enhance her impact profile.

  • Patent/Technology Transfer: Translating her microbial and biocontrol research into patents, prototypes, or industrial-scale applications could broaden societal contributions.

  • Postdoctoral Mentorship: Leading structured postdoctoral mentorship programs could further strengthen her academic leadership credentials.

  • Policy Involvement: Greater involvement in agricultural policy advocacy or consultation at national or FAO-level could expand her influence beyond academia.

🎓 Education:

Dr. Lobna Hajji Ep Hedfi holds a PhD in Agricultural Sciences, specializing in Plant Pathology and Microbial Biotechnology. Her academic background includes comprehensive training in phytopathology, molecular biology, mycology, and biological control, with continuing education under international programs. She participated in capacity-building and professional development through the MSP MENA scholarship program (NUFFIC), funded by the Dutch Ministry of Foreign Affairs. Her formal education has emphasized integrated disease management and the sustainable use of endophytic and rhizosphere microorganisms in crop protection. Her academic journey reflects both national and international excellence, combining practical experience in Tunisian agroecosystems with global innovations in plant-microbe research.

💼 Professional Experience:

Dr. Hajji currently serves as Assistant Professor of Phytopathology at the Regional Centre of Agricultural Research of Sidi Bouzid, Tunisia. She has over a decade of research and teaching experience in plant disease diagnostics, biocontrol strategies, and sustainable agriculture. Her professional journey includes leadership in multi-institutional projects, mentoring graduate students, and active involvement in national and international scientific collaborations. She is a recognized contributor to international journals and has been a part of expert working groups focused on agricultural sustainability. Her fieldwork and applied research directly impact crop resilience and productivity in arid regions. Additionally, her editorial work enhances the visibility and scientific quality of microbiological research.

🏅 Awards and Honors:

  • 🥇 Ethel Mary Doidge Medal for Young Mycologist in Africa – International Mycological Association (IMA), 2024

  • 🎓 MSP Scholarship from NUFFIC, Netherlands – 2023 & 2024

  • 👩‍🔬 Active Editorial Board Member for Microbial Biosystems & Frontiers in Scientific Reports

  • 🧪 Member of SPADD-LR03AGR02: Systems of Agricultural Production and Sustainable Development Laboratory

  • 🌍 Invited speaker and contributor in international symposia on microbial bioresources, endophytic fungi, and CRISPR applications
    These accolades highlight her contributions to phytopathology, sustainable disease control, and scientific communication, emphasizing her leadership potential and impact in African and global agricultural science.

🔬 Research Focus:

Dr. Hajji’s research bridges phytopathology, microbial ecology, and sustainable agriculture. Her work focuses on developing eco-friendly solutions for plant disease management using endophytic fungi, beneficial rhizobacteria, and microbial consortia. She explores plant-microbe interactions, particularly in grapevine and tomato crops, aiming to reduce chemical inputs through biocontrol agents and organic amendments like compost. Her recent interest includes volatile organic compounds (VOCs) from forest fungi, CRISPR applications, and fungal biodiversity mapping. Her integrative approach contributes significantly to combating plant diseases, promoting resilience, and adapting agriculture to climate change. By leveraging omics technologies and field-based experiments, she provides applicable strategies for sustainable crop protection and soil health restoration.

📚 Publications Top Notes: 

  1. 📘 “Omics” tools for better understanding the plant-fungi interactions – Forest Fungi (2025)

  2. 🌿 CRISPR plants for growth and development studies – CRISPR in Sustainable Agriculture (2025)

  3. 🌲 Forest fungal volatile organic compounds (VOCs) – Forest Fungi (2025)

  4. 🍇 Beneficial Rhizobacteria for grapevine health – Frontiers in Sustainable Food Systems (2025)

  5. 🌱 Microbial Consortium & Compost for viticulture disease control – Horticulturae (2025)

  6. 🍋 Phytochemical & antifungal activity of citrus peel extracts – Waste Biomass Valorization (2025)

  7. 🌾 Microbial inoculants for plant resilience – Journal of Plant Diseases & Protection (2025)

  8. 🍄 Fungal endophytes: evolution & ecology – Microbial Biosystems (2025)

  9. 🧫 Bioactive potential of endophytic fungi – Nova Hedwigia (2025)

  10. 🌲 Fungal agents in conifer diseases – Nova Hedwigia (2024)

🔚 Conclusion:

Dr. Lobna Hajji Ep Hedfi demonstrates exceptional promise and productivity as a phytopathologist and microbial ecologist. Her research is innovative, internationally relevant, and directly contributes to sustainable agriculture and climate resilience in Tunisia and beyond. With a strong foundation in publication, international collaboration, and applied microbial research, she is highly suitable for the Best Researcher Award. With continued growth in grant leadership and translational science, she is poised to become one of Africa’s leading researchers in agricultural biotechnology.

Sola Ogunmodede | Host-Pathogen Interactions | Best Researcher Award

Published on by Cell Biologist

Mr. Sola Ogunmodede | Host-Pathogen Interactions | Best Researcher Award

Mr. Sola Ogunmodede, Helix Biogen Institute, Nigeria

Olusola Peter Ogunmodede is a microbiologist and researcher at Helix Biogen Institute, Ogbomoso, Nigeria, specializing in medical mycology, fungal genomics, and bioinformatics diagnostics. He earned his MSc in Microbiology from the University of Lagos, where he investigated Neurospora crassa’s growth and mating patterns, and a B.Tech from LAUTECH, where he focused on bioactive fungal metabolites. He is passionate about addressing global health threats through innovative, cost-effective diagnostic tools, especially in resource-limited settings. Olusola has co-authored several peer-reviewed publications, including studies on peptide-based diagnostics for cholera and Crimean-Congo hemorrhagic fever, and has led or contributed to antimicrobial and genomic research projects. In addition to his research, he teaches bioinformatics and molecular biology techniques to students and professionals. Through community outreach on Neglected Tropical Diseases (NTDs) and youth mentorship, he combines scientific excellence with civic engagement, making him a rising star in biomedical research.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Extensive Research Contributions: With published works in Biotechnology and Applied Biochemistry, Tropical Journal of Natural Product Research, and In Silico Research in Biomedicine, Mr. Ogunmodede has co-authored impactful studies in infectious disease diagnostics, fungal bioactive compounds, and computational biology.

  2. Interdisciplinary Research: His projects span medical mycology, bioinformatics, environmental microbiology, and biotechnology, showing adaptability and scientific depth.

  3. Leadership Experience: Progressed from Assistant Project Manager to Project Manager at Helix Biogen Institute, evidencing strong organizational and scientific leadership capabilities.

  4. Community and Teaching Involvement: Demonstrated commitment to science communication, mentorship, and community service—notably in NTD awareness and prison outreach.

  5. Technical Expertise: Competent in bioinformatics, NGS, GC-MS, PCR, and fungal metabolite extraction—skills relevant to modern microbiological research.

⚠️ Areas for Improvement:

  1. Independent Research Leadership: While collaborative efforts are commendable, initiating and leading first-author research or grant-funded projects would further strengthen his academic identity.

  2. Global Collaborations: Expanding international partnerships or postdoctoral research exposure could enhance visibility and diversify methodologies.

  3. Data Science Fluency: Building advanced skills in AI-based diagnostics, big data genomics, or machine learning would broaden his research scope.

  4. Publication Frequency: While the quality of his publications is notable, maintaining consistency in publication output across more years would support a long-term scholarly trajectory.

🎓 Education:

Olusola Peter Ogunmodede holds an MSc in Microbiology from the University of Lagos, where he explored carbon utilization and genetic typing of Neurospora crassa. His B.Tech in Microbiology was awarded by Ladoke Akintola University of Technology (LAUTECH), where his research focused on endophytic fungal metabolites and their bioactive compounds using GC-MS. His academic path began with a National Diploma (ND) in Science Laboratory Technology from Federal Polytechnic Bida, with an applied project on aquaculture pond development. Each stage of his education has built a layered expertise in microbial physiology, antimicrobial studies, and bioanalytical techniques. His academic work has consistently integrated field relevance with lab-based precision, culminating in strong publications and practical applications in diagnostics, antimicrobial discovery, and environmental sustainability. His diverse educational background underpins a research philosophy rooted in innovation, interdisciplinary knowledge, and public health impact.

💼 Experience:

Olusola Peter Ogunmodede is currently a Project Manager at Helix Biogen Institute, where he leads diagnostic development projects for cholera, CCHF, and H5N1, manages timelines, trains researchers in bioinformatics, and oversees biodegradability studies. Previously, he served as an Assistant Project Manager, executing similar responsibilities. He also has a background in secondary school teaching, where he taught Biology, Agricultural Science, and Technical Drawing, reflecting his ability to engage at all levels of education. His research experience includes peptide-centric diagnostic design, fungal metabolite analysis, biogas generation, and environmental biodegradation testing. He’s proficient in both traditional microbiology techniques and modern molecular tools like PCR, sequencing, and in silico modeling. Additionally, he’s an Instructor at Helix Biogen, teaching NGS, Sanger sequencing, and basic bioinformatics. His strong balance of project leadership, lab research, and academic teaching makes him a versatile and highly effective researcher.

🔬 Research Focus:

Olusola Peter Ogunmodede’s research centers around the bioactive potential of fungi, molecular diagnostics, and antimicrobial resistance. He is especially interested in the use of fungal metabolites as alternatives to synthetic antimicrobials, and the genetic and physiological profiling of fungi in relation to infectious diseases. His work bridges wet-lab and computational techniques, applying bioinformatics for designing peptide-based diagnostics for diseasesvsuch as cholera, Crimean-Congo hemorrhagic fever, and yaws. He also investigates the biodegradability of medical materials, promoting sustainability in biomedical innovation. Olusola’s MSc work on Neurospora crassa and undergraduate research on endophytic fungi laid the foundation for his continued exploration into fungal biodiversity and its applications. His recent projects employ computational tools to develop point-of-care diagnostic kits, targeting low-resource environments where fast, accurate diagnostics are critical. His goal is to integrate genomic science and public health interventions for disease surveillance and control in tropical regions.

📚 Publications Top Notes:

  1. 🧬 Computational Modeling and Validation of Predicted Diagnostic Peptides for Crimean–Congo’s Disease – Biotechnol Appl Biochem, 2025

  2. 🧪 Innovative Biomarker Design for Cholera Diagnosis through Bioinformatics Analysis – In Silico Research in Biomedicine, 2025

  3. 🍄 Synthesis of Endophytic Fungi Metabolites, Antimicrobial Potentials, and Detection of their Bioactive Molecules Using GC-MS – Tropical Journal of Natural Product Research, 2022

  4. 🦠 Molecular Characterization, Antimicrobial and Larvicidal Potentials of Fungi from Soil Samples of LAUTECH Botanical Garden – Archive of Science & Technology, 2020

🧾 Conclusion:

Olusola Peter Ogunmodede is highly suitable for the Best Researcher Award in view of his technical versatility, impactful publications, leadership in diagnostic tool development, and community engagement. With further investment in independent research leadership and global exposure, he stands out as a promising and emerging scholar in medical microbiology and bioinformatics.

Sophie Paczesny | Immunotherapy | Best Researcher Award

Published on by Cell Biologist

Prof. Sophie Paczesny | Immunotherapy | Best Researcher Award

Prof. Sophie Paczesny, Medical Univeristy of South Carolina, United States

Dr. Sophie Paczesny, M.D., Ph.D., is an internationally recognized leader in immunology and cancer research. Currently, she serves as Professor of Immunology & Pediatrics and the Sally Abney Rose Endowed Chair in Cancer Stem Cell Biology at the Medical University of South Carolina (MUSC). She is also Co-Leader of the Cancer Biology & Immunology Program at the Hollings Cancer Center. With a deep commitment to improving outcomes in hematopoietic cell transplantation, her translational research bridges clinical and laboratory advances in graft-versus-host disease (GVHD), biomarkers, and tumor immunology. Her work has shaped diagnostic and therapeutic strategies across pediatric and adult oncology. Dr. Paczesny’s pioneering studies on dendritic cell vaccines and immune reconstitution have led to impactful, high-citation publications in journals like Blood, JCI Insight, and Journal of Clinical Oncology. She continues to mentor the next generation of physician-scientists while advancing cutting-edge immune-oncology research globally.

Publication Profile: 

Orcid

Scopus

✅ Strengths for the Award:

  1. Pioneering Work in Immunology & Transplantation
    Dr. Paczesny has significantly advanced our understanding of graft-versus-host disease (GVHD) through the development of novel biomarkers, improving diagnostics, patient stratification, and therapeutic decisions in hematopoietic cell transplantation.

  2. High-Impact Publications
    With over 20 influential publications, including in Blood, JCI Insight, Journal of Clinical Oncology, and British Journal of Haematology, she has made consistent contributions to high-impact journals, underscoring the translational value of her work.

  3. Strong Interdisciplinary Background
    Her dual degrees (M.D., Ph.D.), combined with training across mathematics, life sciences, tumor immunology, and cell therapy, enable her to bridge basic science and clinical application effectively.

  4. Leadership and Mentorship
    Holding senior positions such as Professor, Endowed Chair, and Program Co-Leader at MUSC, she demonstrates strong leadership and commitment to fostering academic growth in immunology and pediatrics.

  5. Global and Collaborative Impact
    Her participation in international collaborations and consortia (e.g., Pediatric Transplant and Cellular Therapy Consortium) highlights her global influence and scientific diplomacy.

  6. Innovative Clinical Translation
    She led or contributed to the development of decision-support tools (e.g., biomarker-based decision trees for VOD/SOS), which have the potential to shift real-world clinical practices.

⚙️ Areas for Improvement:

  1. Outreach & Visibility
    Despite her extensive contributions, Dr. Paczesny may benefit from more frequent keynote talks, scientific media presence, or public engagement efforts to raise broader awareness of her work among policymakers, patients, and industry.

  2. Startup/Commercial Translation
    While highly research-driven, expanding into biotech or diagnostic tool commercialization could further translate her biomarker discoveries into scalable clinical solutions.

  3. Grant Leadership Details
    The provided information doesn’t detail the scope of grants led (e.g., NIH R01s, consortia P01s). Adding these details could strengthen evaluations by funding and award committees.

🎓 Education:

Dr. Paczesny began her academic journey in France, earning a B.S. in Mathematics and Life Sciences from the Academy of Nancy-Metz (1985–1989). She pursued her M.D. at the University of Strasbourg, completing her medical degree in 1995. Her passion for cellular therapies led her to obtain an M.S. in Cell Therapy and Biology of Hematopoietic Cells from the University of Paris VII in 1999. She continued her scientific training by earning a Ph.D. in Tumor Immunology at the same institution in 2004. Her educational background reflects a unique blend of clinical training and basic science, providing the foundation for her translational research in immunology and cancer biology. This multidisciplinary training has enabled her to tackle complex clinical problems like graft-versus-host disease and immune response modulation from both therapeutic and mechanistic angles.

🩺 Professional Experience:

Dr. Sophie Paczesny has held academic and clinical positions in both Europe and the United States. She began her faculty career as Assistant Professor of Pediatrics at the University and Hospitals of Nancy (2003–2005). She transitioned to the U.S. as Assistant Professor of Pediatrics and Communicable Diseases at the University of Michigan (2009–2012). From 2012–2015, she served as Associate Professor at Indiana University School of Medicine, holding appointments in Pediatrics, Microbiology, and Immunology. She also contributed to the Melvin and Bren Simon Cancer Center. Currently, she is a Professor at the Medical University of South Carolina (MUSC), where she leads research and training efforts in immunology and cancer biology. Across all roles, she has led NIH-funded programs, advanced biomarker research, mentored junior investigators, and contributed to the development of immunotherapeutic approaches in hematopoietic cell transplantation and cancer.

🏅 Honors and Awards:

Dr. Paczesny has received numerous honors recognizing her contributions to science and medicine. In 1999, she earned Second Prize at the Avicenne Hospital Research Meeting in Paris. In 2000, she was awarded the Médaille d’Argent (Silver Medal) from Paris University Hospitals’ residency program. That same year, she co-received First Prize for Best Fellow Academic Work in France, acknowledging her early excellence in clinical and research training. Her ongoing research has been consistently supported by competitive grants and featured in high-impact journals, highlighting her leadership in biomarker discovery and immune-oncology. As an endowed chair at MUSC and an invited speaker at leading international conferences, her work continues to gain recognition. These awards underscore both her clinical insight and scientific innovation, particularly in the fields of transplant immunology and cancer immunotherapy.

🔬 Research Focus:

Dr. Paczesny’s research is centered on translational immunology, with a special focus on graft-versus-host disease (GVHD), immune reconstitution, and cancer immunotherapy. She has pioneered the use of biomarkers to predict outcomes and complications in hematopoietic stem cell transplantation, including veno-occlusive disease and chronic GVHD. Her studies have uncovered novel immune pathways and prognostic indicators, many of which have informed clinical trials and therapeutic strategies. Additionally, she explores dendritic cell vaccines, immunopeptidomics, and HLA allele influences on transplant success. Her collaborative projects span pediatric and adult immunology, contributing to national consortia such as the Pediatric Transplant and Cellular Therapy Consortium. Her ultimate goal is to enhance survival while reducing toxicities of transplantation through immune-guided, precision medicine approaches. She is especially known for integrating advanced statistical modeling and immunobiology to address real-world clinical challenges.

📚 Publications Top Notes: 

  1. 🧫 Protection of mice against leukemia after vaccination with dendritic cells – Cancer Research (2001)

  2. 💉 Monoclonal anti-IL-6 antibody treatment in B-lymphoproliferative disorder – Blood (2001)

  3. 🧬 CD34+ dendritic cell vaccine induces T-cell immunity in melanoma – J Immunother (2003)

  4. 🦠 Dendritic cells as immune controllers and therapeutic tools – Ann NY Acad Sci (2003)

  5. 🎯 Dendritic cells as vectors for cancer immunotherapy – Semin Cancer Biol (2003)

  6. 🧪 Melanoma vaccines using dendritic cells – Dev Biol Basel (2004)

  7. 🧫 CD8+ T-cell expansion in melanoma patients post-vaccination – J Exp Med (2004)

  8. 🧾 Tumor inhibition assay for CTL response post-vaccine – J Immunother (2005)

  9. 🔁 Peptide-pulsed dendritic cells boost melanoma-specific CD8+ T cells – J Immunother (2005)

  10. 📈 Advances in dendritic cell-based immunotherapy – Adv Exp Med Biol (2005)

🧾 Conclusion:

Dr. Sophie Paczesny embodies the ideal recipient of the Best Researcher Award. She has made transformative contributions to immunology, stem cell biology, and cancer therapeutics, particularly in the field of biomarker-driven precision medicine. Her leadership in both academia and collaborative clinical research has shaped safer and more effective treatment strategies for transplant patients worldwide.

Her depth of expertise, sustained research output, and ongoing innovations place her at the forefront of translational immunology. While minor gains could be made in public visibility and translational enterprise, her impact on science and patient care is profound.

Lin Jin | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Lin Jin | Stem Cell Research | Best Researcher Award

Assist. Prof. Dr. Lin Jin, university of alabama at birmingham, United States

Dr. Lin Jin, PhD, is a leading biomedical scientist specializing in cancer biology and dermatological diseases. Currently affiliated with the Department of Dermatology at the University of Alabama at Birmingham (UAB), Dr. Jin has over 15 years of experience in translational research with a focus on epithelial cell biology, stemness, and inflammation. His research has significantly contributed to the understanding of hidradenitis suppurativa and colorectal cancer. Dr. Jin has held postdoctoral fellowships at both Vanderbilt University and UAB and earned his Ph.D. in Biomedical Engineering from Jinan University, China. As a first and co-corresponding author in several high-impact journals, including PNAS, Nature Communications, and Cancer Research, Dr. Jin is known for his cutting-edge work in molecular mechanisms underlying oncogenesis and inflammatory skin diseases. His dedication to science, paired with strong collaborative leadership, has earned him recognition, including a Best Research Poster award at the Southeastern Consortium for Dermatology in 2023.

Publication Profile:

Google Scholar

Orcid

✅ Strengths for the Award:

  1. High-Impact Publications:
    Dr. Jin has consistently published in top-tier journals including PNAS, Nature Communications, Cancer Research, and Gastroenterology. He has multiple first-author and co-corresponding author credits, which underscores his leadership in research.

  2. Translational Research Excellence:
    His work bridges basic science and clinical application, particularly in hidradenitis suppurativa (HS) and cancer biology, contributing both to understanding molecular mechanisms and developing models for therapeutic screening.

  3. Interdisciplinary Expertise:
    Dr. Jin’s research spans stem cell biology, epigenetics, cancer signaling, and dermatological inflammation, showcasing a rare and valuable interdisciplinary scope.

  4. Award-Winning Research:
    He received the Best Research Poster Award at the 2023 Southeastern Consortium for Dermatology, a competitive and peer-reviewed platform.

  5. Consistent Productivity:
    Over 20 peer-reviewed publications in just over a decade reflect sustained scientific output, with several articles receiving high citation counts.

  6. Academic Mentorship and Collaboration:
    Active involvement in multi-author studies and mentorship roles indicate his collaborative nature and influence in team science.

  7. Recognition by Institution:
    His Nature Communications study was highlighted as a UAB Featured Discovery, which reflects institutional validation of research impact.

⚙️ Areas for Improvement:

  1. Independent PI Track:
    While Dr. Jin has a robust publication record, formal documentation of his role as a Principal Investigator (PI) on grants or independent funding initiatives could further strengthen his candidacy.

  2. Broader Leadership Roles:
    Participation in grant review panels, editorial boards, or leadership within professional societies (e.g., SID committees) would demonstrate a broader academic influence.

  3. Expanded Recognition:
    Additional national or international awards and invited keynote lectures could enhance his external profile and leadership visibility in the field.

🎓 Education:

Dr. Lin Jin’s academic journey reflects a deep commitment to biomedical sciences. He earned his Ph.D. in Biomedical Engineering in 2009 from Jinan University, Guangzhou, China, where he developed expertise in proteomics and molecular biology. Following his doctoral studies, he pursued two consecutive postdoctoral fellowships in Cancer Biology—first at Vanderbilt University (2009–2012), and then at the University of Alabama at Birmingham (2012–2013). These positions enabled him to gain advanced experience in translational research, stem cell biology, and oncogenic signaling pathways. Throughout his education, Dr. Jin focused on the molecular basis of cancer development, particularly exploring signaling pathways and gene regulation. His multidisciplinary training in engineering, biology, and cancer research laid the groundwork for his later success in dermatological research. This diverse academic background has empowered him to lead interdisciplinary projects that bridge basic science and clinical dermatology.

💼 Experience:

Dr. Jin has extensive research experience across prestigious institutions. His career began in China, where he contributed to proteomics and apoptosis research. He then advanced his expertise through postdoctoral roles at Vanderbilt University (2009–2012), working on stemness and epigenetics, and at the University of Alabama at Birmingham (2012–2013), focusing on epithelial biology and inflammation. Since then, he has served as a senior researcher in UAB’s Department of Dermatology, leading numerous projects on hidradenitis suppurativa, colorectal cancer, and stem cell signaling. Dr. Jin has authored over 20 high-impact publications and plays an active role in collaborative research, working with interdisciplinary teams including dermatologists, molecular biologists, and oncologists. His work has directly contributed to therapeutic advancements and better molecular understanding of chronic inflammatory diseases and cancer. As a co-corresponding author and lab leader, he has mentored junior researchers, making him not just a scientist but a key figure in translational medicine.

🏅 Awards and Honors:

Dr. Lin Jin has received notable recognition for his scientific achievements. Most recently, he was honored with the Best Research Poster Award at the 46th Annual Southeastern Consortium for Dermatology in 2023, held in Birmingham, Alabama. This award recognized his pioneering work on epigenetic mechanisms in hidradenitis suppurativa. His work published in Nature Communications was featured as UAB’s Featured Discovery in 2021, underlining the impact of his research in stem cell biology. His contributions have also led to multiple publications in top-tier journals, a testament to his excellence and innovation. Additionally, Dr. Jin has been an active member of the Society for Investigative Dermatology (SID) since 2022, further cementing his role in the dermatological research community. These accolades highlight his consistent drive to advance science and address pressing clinical problems with molecular insight and translational application.

🔬 Research Focus:

Dr. Jin’s research centers around molecular pathogenesis of inflammatory and neoplastic skin diseases, especially hidradenitis suppurativa, a chronic inflammatory condition. His work explores epigenetic regulation, epithelial stem cell dynamics, alternative splicing, and tumorigenesis. His innovative studies use ex vivo models, genomic profiling, and pathway analysis to unravel how dysregulated signaling in epithelial progenitor cells drives both inflammation and hyperproliferation. He has also contributed substantially to understanding cancer stemness and EMT, particularly in colorectal and lung cancers, emphasizing the role of STRAP and Notch/Wnt signaling. Dr. Jin is at the forefront of integrating bioengineering, stem cell biology, and dermatology to discover novel therapeutic strategies. His current projects involve mapping epigenetic switches, developing culture models for drug testing, and identifying biomarkers for skin inflammation and cancer. This integrative and translational approach makes his research highly relevant for both academic advancement and clinical impact.

📚 Publication Top Notes: 

  1. 📘 Epigenetic switch reshapes epithelial progenitor cell signatures and drives inflammatory pathogenesis in hidradenitis suppurativa – PNAS, 2023

  2. 🧬 Mechanism underlying follicular hyperproliferation and oncogenesis in hidradenitis suppurativa – iScience, 2023

  3. 💊 Combined Inhibition of BET Bromodomain and mTORC1/2 Provides Therapeutic Advantage for Rhabdomyosarcoma – Mol Carcinog, 2022

  4. 🧫 Ex Vivo Culture Models of Hidradenitis Suppurativa for Defining Molecular Pathogenesis and Treatment Efficacy – Inflammation, 2022

  5. 🧩 Advances in molecular pathogenesis of hidradenitis suppurativa: Dysregulated keratins and ECM signaling – Semin Cell Dev Biol, 2022

  6. 🧠 STRAP as a mediator of APC mutation-induced intestinal tumorigenesis via a feed-forward mechanism – Gastroenterology, 2021

  7. 🔄 STRAP regulates alternative splicing fidelity during mouse embryonic stem cell lineage commitment – Nat Commun, 2020

  8. 🧪 STRAP deficiency impairs stem cell commitment via retinoic acid dysregulation – Stem Cells, 2018

  9. 🔬 STRAP promotes stemness in colorectal cancer via Notch epigenetic regulation – Cancer Res, 2017

  10. 🧱 TGF-ß-induced Claudin-4 expression via c-Jun signaling in NSCLC – Cell Signal, 2016

📝 Conclusion:

Dr. Lin Jin exemplifies the qualities of an outstanding and impactful researcher. His research has meaningfully advanced the molecular understanding of both inflammatory dermatological disorders and oncogenesis. His strong publication record, interdisciplinary expertise, and recognition within the dermatology and cancer biology communities make him a highly suitable candidate for the Best Researcher Award.